Polymer Capital Management HK LTD Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Polymer Capital Management HK LTD bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 64,957 shares of the biopharmaceutical company’s stock, valued at approximately $19,554,000. Alnylam Pharmaceuticals comprises approximately 1.0% of Polymer Capital Management HK LTD’s portfolio, making the stock its 10th biggest position.

Other large investors also recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after purchasing an additional 151,480 shares during the last quarter. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $895,816,000. Orbis Allan Gray Ltd lifted its position in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Alnylam Pharmaceuticals by 8.3% during the 4th quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock worth $382,339,000 after acquiring an additional 73,716 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 23.6% in the 4th quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after acquiring an additional 175,951 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. dropped their price target on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. HC Wainwright cut their price objective on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a report on Friday, July 31st. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research note on Friday, July 31st. Finally, Sanford C. Bernstein raised shares of Alnylam Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $386.62.

Insiders Place Their Bets

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $236.22 on Monday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $31.61 billion, a PE ratio of 43.91 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55. The stock has a 50-day simple moving average of $267.02 and a two-hundred day simple moving average of $297.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the firm posted ($0.51) earnings per share. The company’s revenue for the quarter was up 66.9% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.